Know Cancer

forgot password

18 Years
50 Years
Not Enrolling
Obesity, Overweight

Thank you

Trial Information

Obesity is associated with sub-clinical chronic oxidative and inflammatory stress, both of
which are major contributors to obesity-associated co-morbidities. Calcitriol (1,
25-(OH)2-D3) regulates adipocyte lipid metabolism, while dietary calcium inhibits obesity by
suppression of calcitriol. We have recently shown calcitriol to increase oxidative stress
and to stimulate the expression and release of inflammatory cytokines, while inhibiting the
expression and release of anti-inflammatory cytokines. We have also shown that inhibition
of calcitriol with high calcium diets decreases both adipose tissue and systemic oxidative
and inflammatory stress in a mouse model of obesity. Moreover, dairy exerted a greater
effect on both oxidative and inflammatory stress. These mice also exhibited significant
reductions in adiposity, which could lead to confounding, as this reduction will
independently reduce oxidative and inflammatory stress. However, the supporting
cellular/mechanistic data indicate an effect which is independent of adiposity reduction.
Consequently, we propose that low calcium diets exacerbate oxidative and inflammatory stress
and that high dairy diets can attenuate both independently of changes in adiposity, thereby
significantly reducing the risk of obesity-associated co-morbidities. Accordingly, the
objective of this study is to determine the acute effects of a dairy-rich diet on oxidative
and inflammatory stress in overweight and obese subjects in the absence of any changes in

Twenty subjects (10 obese and 10 overweight) will undergo a randomized crossover study of
low dairy and high dairy eucaloric diets. Each dietary period will be four weeks, and the
two dietary periods will be separated by a four-week washout period. Primary outcomes will
be circulating indices of oxidative stress and of inflammation. Secondary outcomes include
blood pressure, circulating glucose, insulin, lipids, calcium-regulatory hormones and body

Inclusion Criteria:

- Body mass index (BMI) 25-29.9 (n=10); 30-34.9 kg/m2 (n=10)

- Age 18-50 years

- Weight stable: no more than 3 kg weight loss during past three months

Exclusion Criteria:

- BMI < 25 or >35

- Type II diabetes requiring the use of any oral antidiabetic agent and/or insulin
(because of confounding effects on ROS)

- Adverse response to study foods (lactose intolerance, dairy intolerance, dairy
allergy); this will be determined by self-report.

- history or presence of significant metabolic disease which could impact on the
results of the study (i.e. endocrine, hepatic, renal disease)

- history of eating disorder

- presence of active gastrointestinal disorders such as malabsorption syndromes

- pregnancy or lactation

- use of obesity pharmacotherapeutic agents within the last 6 months

- use of over-the-counter anti-obesity agents (e.g. those containing
phenylpropanalamine, ephedrine and/or caffeine) within the last 6 months

- Recent (current or past 12 weeks) use of any psychotropic medication

- Recent (past four weeks) initiation of an exercise program

- Recent (past twelve weeks) initiation of hormone replacement therapy or change in HRT

- Recent (past twelve weeks) initiation of hormonal birth control or change in hormonal
birth control regimen

- Recent (current or past 12 weeks) history of smoking

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Outcome Measure:

Plasma malondialdehyde

Outcome Time Frame:

28 days

Safety Issue:



United States: Institutional Review Board

Study ID:




Start Date:

January 2007

Completion Date:

May 2009

Related Keywords:

  • Obesity
  • Overweight
  • Inflammation
  • Oxidative stress
  • Obesity
  • Overweight



The University of TennesseeKnoxville, Tennessee  37996